Takaisin Tulosta

MS-tauti, näytönastekatsausten kirjallisuusviitteet

Lisätietoa aiheesta
Käypä hoito -toimitus
6.2.2024

Kirjallisuusviiteluettelosta löytyy koottuna Käypä hoito -suosituksen MS-tauti «MS-tauti»1 näytönastekatsauksissa arvioitu kirjallisuus.

Kirjallisuutta

  1. Alping P, Burman J, Lycke J, ym. Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple Sclerosis. Neurology 2021;96(11):e1574-e1584 «PMID: 33514645»PubMed
  2. Ashkar A, Baig MMA, Arif A, ym. Prognostic significance of neurofilament light in Fingolimod therapy for Multiple Sclerosis: A systemic review and meta-analysis based on randomized control trials. Mult Scler Relat Disord 2023;69():104416 «PMID: 36495843»PubMed
  3. Atkins HL, Bowman M, Allan D, ym. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial. Lancet 2016;388(10044):576-85 «PMID: 27291994»PubMed
  4. Bar-Or A, Grove RA, Austin DJ, ym. Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study. Neurology 2018;90(20):e1805-e1814 «PMID: 29695594»PubMed
  5. Benkert P, Meier S, Schaedelin S, ym. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. Lancet Neurol 2022;21(3):246-257 «PMID: 35182510»PubMed
  6. Berriozabalgoitia R, Bidaurrazaga-Letona I, Otxoa E, ym. Overground Robotic Program Preserves Gait in Individuals With Multiple Sclerosis and Moderate to Severe Impairments: A Randomized Controlled Trial. Arch Phys Med Rehabil 2021;102(5):932-939 «PMID: 33316225»PubMed
  7. Boffa G, Massacesi L, Inglese M, ym. Long-term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis. Neurology 2021;96(8):e1215-e1226 «PMID: 33472915»PubMed
  8. Bonzano L, Pedulla L, Tacchino A ym. Upper limb motor training based on task-oriented exercises induces functional brain reorganization in patients with multiple sclerosis. Neuroscience. 2019;410:150-9
  9. Bowman T, Gervasoni E, Amico AP, ym. What is the impact of robotic rehabilitation on balance and gait outcomes in people with multiple sclerosis? A systematic review of randomized control trials. Eur J Phys Rehabil Med 2021;57(2):246-253 «PMID: 33541044»PubMed
  10. Brune S, Høgestøl EA, de Rodez Benavent SA, ym. Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis. Mult Scler 2022;28(12):1859-1870 «PMID: 35658739»PubMed
  11. Buchmann A, Pirpamer L, Pinter D, ym. High serum neurofilament light chain levels correlate with brain atrophy and physical disability in multiple sclerosis. Eur J Neurol 2023;30(5):1389-1399 «PMID: 36779855»PubMed
  12. Burt RK, Balabanov R, Burman J, ym. Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial. JAMA 2019;321(2):165-174 «PMID: 30644983»PubMed
  13. Butzkueven H, Kappos L, Spelman T, ym. No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score-matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP). Ther Adv Neurol Disord 2021;14():17562864211042458 «PMID: 34603507»PubMed
  14. Camu W, Lehert P, Pierrot-Deseilligny C, ym. Cholecalciferol in relapsing-remitting MS: A randomized clinical trial (CHOLINE). Neurol Neuroimmunol Neuroinflamm 2019;6(5): «PMID: 31454777»PubMed
  15. Cantó E, Barro C, Zhao C, ym. Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years. JAMA Neurol 2019;76(11):1359-1366 «PMID: 31403661»PubMed
  16. Chen Y, Xu S, Shen J, ym. Effect of Exercise on Fatigue in Multiple Sclerosis Patients: A Network Meta-analysis. Int J Sports Med 2021;42(14):1250-1259 «PMID: 34375988»PubMed
  17. Cohen JA, Imrey PB, Planchon SM, ym. Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis. Mult Scler 2018;24(4):501-511 «PMID: 28381130»PubMed
  18. Comi G, Cook S, Giovannoni G, ym. Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis. Mult Scler Relat Disord 2019;29():168-174 «PMID: 30885375»PubMed
  19. Comi G, Cook S, Rammohan K ym. Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing-remitting multiple sclerosis: the CLARITY Extension study. Ther Adv Neurol Disord. 2018;11: 1-11 
  20. Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 2001;49(3):290-7 «PMID: 11261502»PubMed
  21. Cook S, Leist T, Comi G, ym. Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis. Mult Scler Relat Disord 2019;29():157-167 «PMID: 30885374»PubMed
  22. das Nair R, Martin KJ, Lincoln NB. Memory rehabilitation for people with multiple sclerosis. Cochrane Database Syst Rev 2016;3():CD008754 «PMID: 27004596»PubMed
  23. Delcoigne B, Manouchehrinia A, Barro C, ym. Blood neurofilament light levels segregate treatment effects in multiple sclerosis. Neurology 2020;94(11):e1201-e1212 «PMID: 32047070»PubMed
  24. Di Tella S, Pagliari C, Blasi V, ym. Integrated telerehabilitation approach in multiple sclerosis: A systematic review and meta-analysis. J Telemed Telecare 2020;26(7-8):385-399 «PMID: 31132909»PubMed
  25. Edan G, Miller D, Clanet M, ym. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997;62(2):112-8 «PMID: 9048709»PubMed
  26. Filippini G, Kruja J, Del Giovane C. Rituximab for people with multiple sclerosis. Cochrane Database Syst Rev 2021;11(11):CD013874 «PMID: 34748215»PubMed
  27. Foley JF, Defer G, Ryerson LZ, ym. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial. Lancet Neurol 2022;21(7):608-619 «PMID: 35483387»PubMed
  28. Freedman MS and PRISMS Study Group. PRISMS 4-year results: Evidence of clinical dose effect of interferon beta-1a in relapsing MS. Neurology 2000;54:2350
  29. Gandolfi M, Valè N, Dimitrova EK, ym. Effects of High-intensity Robot-assisted Hand Training on Upper Limb Recovery and Muscle Activity in Individuals With Multiple Sclerosis: A Randomized, Controlled, Single-Blinded Trial. Front Neurol 2018;9():905 «PMID: 30405526»PubMed
  30. Gervasoni E, Cattaneo D, Bertoni R ym. Effect of arm cycling and task-oriented exercises on fatigue and upper limb performance in multiple sclerosis: a randomized crossover study. International Journal of Rehabilitation Research. 2019;42(4):300-8.
  31. Giovannoni G, Comi G, Cook S, ym. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010;362(5):416-26 «PMID: 20089960»PubMed
  32. Giovannoni G, Soelberg Sorensen P, Cook S, ym. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. Mult Scler 2018;24(12):1594-1604 «PMID: 28870107»PubMed
  33. Goodman AD, Rossman H, Bar-Or A, ym. GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study. Neurology 2009;72(9):806-12 «PMID: 19255407»PubMed
  34. Hao Z, Zhang X, Chen P. Effects of Different Exercise Therapies on Balance Function and Functional Walking Ability in Multiple Sclerosis Disease Patients-A Network Meta-Analysis of Randomized Controlled Trials. Int J Environ Res Public Health 2022;19(12): «PMID: 35742424»PubMed
  35. Hartung HP, Gonsette R, König N, ym. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002;360(9350):2018-25 «PMID: 12504397»PubMed
  36. Hauser SL, Bar-Or A, Cohen JA, ym. Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med 2020;383(6):546-557 «PMID: 32757523»PubMed
  37. Hauser SL, Bar-Or A, Comi G ym. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med 2017;376:221-234 
  38. He D, Zhang C, Zhao X, ym. Teriflunomide for multiple sclerosis. Cochrane Database Syst Rev 2016;3(3):CD009882 «PMID: 27003123»PubMed
  39. https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-restricting-use-modafinil_en.pdf «https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-restricting-use-modafinil_en.pdf»1 (Siteerattu 31.10.2022)
  40. Hupperts R, Smolders J, Vieth R, ym. Randomized trial of daily high-dose vitamin D(3) in patients with RRMS receiving subcutaneous interferon β-1a. Neurology 2019;93(20):e1906-e1916 «PMID: 31594857»PubMed
  41. Hvid LG, Gaemelke T, Dalgas U, ym. Personalised inpatient multidisciplinary rehabilitation elicits clinically relevant improvements in physical function in patients with multiple sclerosis - The Danish MS Hospitals Rehabilitation Study. Mult Scler J Exp Transl Clin 2021;7(1):2055217321989384 «PMID: 33643662»PubMed
  42. Häring DA, Kropshofer H, Kappos L, ym. Long-term prognostic value of longitudinal measurements of blood neurofilament levels. Neurol Neuroimmunol Neuroinflamm 2020;7(5): «PMID: 32817406»PubMed
  43. . Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 1995;45(7):1277-85 «PMID: 7617182»PubMed
  44. . Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 1993;43(4):655-61 «PMID: 8469318»PubMed
  45. Jacobs LD, Cookfair DL, Rudick RA ym. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) Ann Neurol 1996;39:285-94 
  46. Jagannath VA, Filippini G, Di Pietrantonj C, ym. Vitamin D for the management of multiple sclerosis. Cochrane Database Syst Rev 2018;9(9):CD008422 «PMID: 30246874»PubMed
  47. Johnson KP, Brooks BR, Cohen JA, ym. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995;45(7):1268-76 «PMID: 7617181»PubMed
  48. Johnson KP, Brooks BR, Cohen JA, ym. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology 1998;50(3):701-8 «PMID: 9521260»PubMed
  49. Johnson KP, Brooks BR, Ford CC, ym. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. Mult Scler 2000;6(4):255-66 «PMID: 10962546»PubMed
  50. Kajbafvala M, Ashnagar Z, Lucio A, ym. Pelvic floor muscle training in multiple sclerosis patients with lower urinary tract dysfunction: A systematic review and meta-analysis. Mult Scler Relat Disord 2022;59():103559 «PMID: 35144089»PubMed
  51. Kalron A, Greenberg-Abrahami M, Gelav S, ym. Effects of a new sensory re-education training tool on hand sensibility and manual dexterity in people with multiple sclerosis. NeuroRehabilitation 2013;32(4):943-8 «PMID: 23867419»PubMed
  52. Kamm CP, Mattle HP, Müri RM, ym. Home-based training to improve manual dexterity in patients with multiple sclerosis: A randomized controlled trial. Mult Scler 2015;21(12):1546-56 «PMID: 25623246»PubMed
  53. Kapoor R, Ho PR, Campbell N, ym. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurol 2018;17(5):405-415 «PMID: 29545067»PubMed
  54. Kappos L, Bar-Or A, Cree BAC, ym. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet 2018;391(10127):1263-1273 «PMID: 29576505»PubMed
  55. Kappos L, Fox RJ, Burcklen ym. Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 OPTIMUM study: A randomized clinical trial. JAMA Neurol 2021;78:558-567
  56. Kira JI, Nakahara J, Sazonov DV, ym. Effect of ofatumumab versus placebo in relapsing multiple sclerosis patients from Japan and Russia: Phase 2 APOLITOS study. Mult Scler 2022;28(8):1229-1238 «PMID: 34787005»PubMed
  57. Kuhle J, Disanto G, Lorscheider J, ym. Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis. Neurology 2015;84(16):1639-43 «PMID: 25809304»PubMed
  58. Kuhle J, Kropshofer H, Haering DA ym. Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. Neurology 2019; 92: e1007-e1015
  59. Kuhle J, Plavina T, Barro C ym. Neurofilament light levels are associated with long-term outcomes in multiple sclerosis. Mult Scler 2020;26(13):1691-1699, PMID: 31680621
  60. La Mantia L, Tramacere I, Firwana B, ym. Fingolimod for relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev 2016;4(4):CD009371 «PMID: 27091121»PubMed
  61. Leist T, Cook S, Comi G, ym. Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis. Mult Scler Relat Disord 2020;46():102572 «PMID: 33296971»PubMed
  62. Leist TP, Comi G, Cree BA, ym. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Lancet Neurol 2014;13(3):257-67 «PMID: 24502830»PubMed
  63. Leppert D, Kropshofer H, Häring DA, ym. Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials. Neurology 2022;98(21):e2120-e2131 «PMID: 35379762»PubMed
  64. Li DK, Paty DW. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in Multiple Sclerosis. Ann Neurol 1999;46(2):197-206 «PMID: 10443885»PubMed
  65. Llufriu S, Sepúlveda M, Blanco Y, ym. Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis. PLoS One 2014;9(12):e113936 «PMID: 25436769»PubMed
  66. Lublin F, Miller DH, Freedman MS, ym. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2016;387(10023):1075-1084 «PMID: 26827074»PubMed
  67. Mancardi GL, Sormani MP, Gualandi F, ym. Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial. Neurology 2015;84(10):981-8 «PMID: 25672923»PubMed
  68. Mark VW, Taub E, Uswatte G, ym. Phase II Randomized Controlled Trial of Constraint-Induced Movement Therapy in Multiple Sclerosis. Part 1: Effects on Real-World Function. Neurorehabil Neural Repair 2018;32(3):223-232 «PMID: 29668399»PubMed
  69. Martinelli Boneschi F, Vacchi L, Rovaris M, ym. Mitoxantrone for multiple sclerosis. Cochrane Database Syst Rev 2013;(5):CD002127 «PMID: 23728638»PubMed
  70. Millefiorini E, Gasperini C, Pozzilli C, ym. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 1997;244(3):153-9 «PMID: 9050955»PubMed
  71. Miller DH, Khan OA, Sheremata WA, ym. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003;348(1):15-23 «PMID: 12510038»PubMed
  72. Monreal E, Fernández-Velasco JI, García-Sánchez MI, ym. Association of Serum Neurofilament Light Chain Levels at Disease Onset With Disability Worsening in Patients With a First Demyelinating Multiple Sclerosis Event Not Treated With High-Efficacy Drugs. JAMA Neurol 2023;80(4):397-403 «PMID: 36848127»PubMed
  73. Montalban X, Gold R, Thompson AJ, ym. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler 2018;24(2):96-120 «PMID: 29353550»PubMed
  74. Montalban X, Hauser SL, Kappos L, ym. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med 2017;376(3):209-220 «PMID: 28002688»PubMed
  75. Muraro PA, Pasquini M, Atkins HL ym. Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis. JAMA Neurol 2017;74:459-469
  76. Möller F, Poettgen J, Broemel F, ym. HAGIL (Hamburg Vigil Study): a randomized placebo-controlled double-blind study with modafinil for treatment of fatigue in patients with multiple sclerosis. Mult Scler 2011;17(8):1002-9 «PMID: 21561959»PubMed
  77. Nash RA, Hutton GJ, Racke MK ym. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report. JAMA Neurol 2015;72:159-69
  78. Ning L, Wang B. Neurofilament light chain in blood as a diagnostic and predictive biomarker for multiple sclerosis: A systematic review and meta-analysis. PLoS One 2022;17(9):e0274565 «PMID: 36103562»PubMed
  79. Nourbakhsh B, Revirajan N, Morris B ym. Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial. Lancet Neurol. 2021;20(1):38-48.
  80. Olsson T, Boster A, Fernández Ó ym. Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial J Neurol Neurosurg Psychiatry. 2014;85:1198-208
  81. Pappalardo A, D’Amico E, Leone C, ym. Inpatient versus outpatient rehabilitation for multiple sclerosis patients: effects on disability and quality of life. Multiple Sclerosis and Demyelinating Disorders 2016;volume 1, Article number: 3
  82. Paty DW, Li DK. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 1993;43(4):662-7 «PMID: 8469319»PubMed
  83. Plavina T, Fox EJ, Lucas N, ym. A Randomized Trial Evaluating Various Administration Routes of Natalizumab in Multiple Sclerosis. J Clin Pharmacol 2016;56(10):1254-62 «PMID: 26835603»PubMed
  84. Polman CH, O'Connor PW, Havrdova E, ym. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354(9):899-910 «PMID: 16510744»PubMed
  85. Pompa A, Morone G, Iosa M, ym. Does robot-assisted gait training improve ambulation in highly disabled multiple sclerosis people? A pilot randomized control trial. Mult Scler 2017;23(5):696-703 «PMID: 27486219»PubMed
  86. Rammohan KW, Rosenberg JH, Lynn DJ ym. Efficacy and safety of modafinil (Provigil®) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 studyJournal of Neurology, Neurosurgery & Psychiatry 2002;72:179-183.
  87. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998;352(9139):1498-504 «PMID: 9820297»PubMed
  88. Riera R, Torloni MR, Martimbianco ALC, ym. Alemtuzumab for multiple sclerosis. Cochrane Database Syst Rev 2023;6(6):CD011203 «PMID: 37272540»PubMed
  89. Rintala A, Hakala S, Paltamaa J, ym. Effectiveness of technology-based distance physical rehabilitation interventions on physical activity and walking in multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials. Disabil Rehabil 2018;40(4):373-387 «PMID: 27973919»PubMed
  90. Robert T. Naismith RT, Wundes A, Ziemssen T ym. on behalf of The EVOLVE-MS-2 Study Group. Diroximel fumarate demonstrates an improved gastrointestinal tolerability profile compared with dimethyl fumarate in patients with relapsing–remitting multiple sclerosis: results from the randomized, double-blind, phase III EVOLVE-MS-2 study. CNS Drugs 2020;34:185-96
  91. Rosenstein I, Axelsson M, Novakova L ym. Exploring CSF neurofilament light as a biomarker for MS in clinical practice; a retrospective registry-based study. Multiple Sclerosis Journal. 2022;28(6):872-884
  92. Rosti-Otajärvi EM, Hämäläinen PI. Neuropsychological rehabilitation for multiple sclerosis. Cochrane Database Syst Rev 2014;(2):CD009131 «PMID: 24515630»PubMed
  93. Rudick RA, Stuart WH, Calabresi PA, ym. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354(9):911-23 «PMID: 16510745»PubMed
  94. Salhofer-Polanyi S, Windt J, Sumper H, ym. Benefits of inpatient multidisciplinary rehabilitation in multiple sclerosis. NeuroRehabilitation 2013;33(2):285-92 «PMID: 23949063»PubMed
  95. Sanches-Lastra M ym. Pilates for people with multiple sclerosis: A systematic review and meta-analysis. Multiplse sclerosis and related disorders. 2019;28:199-212
  96. Sconza C, Negrini F, Di Matteo B, ym. Robot-Assisted Gait Training in Patients with Multiple Sclerosis: A Randomized Controlled Crossover Trial. Medicina (Kaunas) 2021;57(7): «PMID: 34356994»PubMed
  97. Simon JH, Jacobs LD, Campion M ym. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Ann Neurol 1998;43:79-87 
  98. Smolders J, Hupperts RM, Vieth R. High dose cholecalciferol (vitamin D3) oil as add-on therapy in subjects with relapsing-remitting multiple sclerosis (RRMS) receiving subcutaneous interferon β-1a (scIFNβ-1a). ECTRIMS Online Library 2016, 147013
  99. Sormani MP, Haering DA, Kropshofer H, ym. Blood neurofilament light as a potential endpoint in Phase 2 studies in MS. Ann Clin Transl Neurol 2019;6(6):1081-1089 «PMID: 31211172»PubMed
  100. Sotirchos ES, Fitzgerald KC, Singh CM, ym. Associations of sNfL with clinico-radiological measures in a large MS population. Ann Clin Transl Neurol 2023;10(1):84-97 «PMID: 36427295»PubMed
  101. Stankoff B, Waubant E, Confavreux C, ym. Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. Neurology 2005;64(7):1139-43 «PMID: 15824337»PubMed
  102. Storr LK, Sørensen PS, Ravnborg M. The efficacy of multidisciplinary rehabilitation in stable multiple sclerosis patients. Mult Scler 2006;12(2):235-42 «PMID: 16629429»PubMed
  103. Straudi S, Fanciullacci C, Martinuzzi C, ym. The effects of robot-assisted gait training in progressive multiple sclerosis: A randomized controlled trial. Mult Scler 2016;22(3):373-84 «PMID: 26658817»PubMed
  104. Straudi S, Manfredini F, Lamberti N, ym. Robot-assisted gait training is not superior to intensive overground walking in multiple sclerosis with severe disability (the RAGTIME study): A randomized controlled trial. Mult Scler 2020;26(6):716-724 «PMID: 30829117»PubMed
  105. Svenningsson A, Frisell T, Burman J, ym. Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial. Lancet Neurol 2022;21(8):693-703 «PMID: 35841908»PubMed
  106. Torres-Costoso A, Martínez-Vizcaíno V, Reina-Gutiérrez S, ym. Effect of Exercise on Fatigue in Multiple Sclerosis: A Network Meta-analysis Comparing Different Types of Exercise. Arch Phys Med Rehabil 2022;103(5):970-987.e18 «PMID: 34509464»PubMed
  107. Trojano M, Ramió-Torrentà L, Grimaldi LM, ym. A randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosis. Mult Scler 2021;27(14):2240-2253 «PMID: 33821693»PubMed
  108. Webster A, Poyade M, Rooney S, ym. Upper limb rehabilitation interventions using virtual reality for people with multiple sclerosis: A systematic review. Mult Scler Relat Disord 2021;47():102610 «PMID: 33212400»PubMed
  109. Wesnes K, Myhr KM, Riise T, ym. Low vitamin D, but not tobacco use or high BMI, is associated with long-term disability progression in multiple sclerosis. Mult Scler Relat Disord 2021;50():102801 «PMID: 33636616»PubMed
  110. Xu Z, Zhang F, Sun F, ym. Dimethyl fumarate for multiple sclerosis. Cochrane Database Syst Rev 2015;2015(4):CD011076 «PMID: 25900414»PubMed
  111. Yeh SW, Lin LF, Tam KW, ym. Efficacy of robot-assisted gait training in multiple sclerosis: A systematic review and meta-analysis. Mult Scler Relat Disord 2020;41():102034 «PMID: 32200337»PubMed
  112. Zhukovsky C, Sandgren S, Silfverberg T, ym. Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing-remitting multiple sclerosis: an observational study. J Neurol Neurosurg Psychiatry 2021;92(2):189-194 «PMID: 33106366»PubMed
Artikkelin tunnus: nix03357 (036.070)
© 2024 Suomalainen Lääkäriseura Duodecim

Käypä hoito -suositus

Anna palautetta
Linkkien värikoodit